Very good point eagle8. Also, the control group for the trial, was comprised of 1,366 GBM patients, from 5 contemporaneous external controls arms (ECAs), and who were all treated with the current GBM standard of care (SOC).
That’s a lot of GBM patients to compare the DCVax-L Phase III trial overall survival results to.
I should have been more clear. I meant two or three hundreds of patients from compassionate use program and many of them may receive DCVax-L + Poly-ICLC. The data from these patients should be more amazing than p3 trial.
News 
Market Data 
Discover 
